Under Dr Celniker’s leadership, Taligen intends to build its late-stage R&D operations in Cambridge while maintaining in Denver its early discovery activities that are closely aligned with an international complement biology research network organized by Michael Holers, one of the company’s founders.
Prior to joining Taligen, Dr Celniker was global head of Novartis Biologics. Dr Celniker earned a PhD in molecular biology from the University of Arizona and a BA in biology from the University of California, San Diego.
Tim Mills, Taligen’s chairman and managing director with Sanderling Ventures, said: “I look forward to working with her as we implement our corporate growth plan to build a company focused on the development of a pipeline of protein therapeutics intended for the treatment of diseases where complement dysregulation is implicated.”